USRE42129EExpiredUtility

Viral obesity methods and compositions

Assignee: OBETECH LLCPriority: Apr 4, 1997Filed: Jun 30, 2009Granted: Feb 8, 2011
Est. expiryApr 4, 2017(expired)· nominal 20-yr term from priority
A61K 39/00A61K 39/235G01N 2800/044A61K 39/12C12Q 1/6883C12N 2710/10321G01N 2333/075C12N 2710/10322C07K 2317/76G01N 33/56983C07K 14/005C07K 16/081C12N 7/00C12Q 1/701C12N 2710/10334
76
PatentIndex Score
0
Cited by
4
References
14
Claims

Abstract

A source of viral induced obesity has been discovered. A virus known as AD-36Padenovirus type 36 has been found to be associated with obesity in both animals and humans. Diagnostic DNA sequences are presented so that DNA based tests for the presence of the obesity associated virus can be conducted.

Claims

exact text as granted — not AI-modified
1. A method of determining whether an obese person is suffering from viral obesity caused by adenovirus type 36p, the method comprising the steps of isolating from the person a sample selected from the group consisting of a body fluid, feces, a sample of tissue and a sample of an organ from the person, obtaining an antibody specific to an adenovirus type 36p, and; assaying the sample using the antibody to test for the presence of the adenovirus type 36p thus testing whether the person has been or is infected with adenovirus type 36p, which causes obesity and reduces cholesterol level in humans. 
     
     
       2. The method according to  claim 1  wherein the substance analyzed is blood. 
     
     
       3. A method for the detection of virally caused obesity in an obese subject comprising the steps of
 isolating a sample of biological tissue or fluid from the subject;    providing an antibody specific to adenovirus type 36p;    testing the sample, using the antibody diagnostic for adenovirus type 36p; and    detecting the presence of adenovirus type 36p to determine if the subject has viral induced obesity.    
     
     
       4. A method for predicting a predisposition to virally- induced obesity in a subject comprising the steps of:      obtaining a sample from the subject;        screening for the presence of the nucleic acid sequences specific to adenovirus type  36  in the sample; and        determining the presence of nucleic acid sequences specific to adenovirus type  36  in the subject such that the presence Ad -   36  nucleic acid sequences in the subject correlate with a predisposition of virally - induced obesity.     
     
     
       5. The method of  claim 4 , wherein the nucleic acid sequences specific to adenovirus type  36  are one or more nucleic acid sequences selected from the group consisting of SEQ ID NO:  1 , SEQ ID NO:  2 , SEQ ID NO:  3 , and SEQ ID NO:  4 . 
     
     
       6. The method of  claim 4 , wherein said step of determining the presence of nucleic acid sequences specific to adenovirus type-   36  is performed by one or more methods selected from the group consisting of direct DNA sequencing, RNase protection assays, PCR, RT PCR, and nucleic acid hybridization.   
     
     
       7. The method of  claim 4 , wherein the nucleic acid in said determining step is DNA selected from the group consisting of cDNA, ssDNA, dsDNA, and genomic DNA. 
     
     
       8. The method of  claim 4 , wherein the nucleic acid in said determining step is RNA selected from the group consisting of mRNA, dsRNA, and ssRNA. 
     
     
       9. The method of  claim 4 , wherein the subject is a human. 
     
     
       10. The method of  claim 4 , wherein the subject is a non- human animal.   
     
     
       11. The method of  claim 4 , wherein the sample is a biological sample. 
     
     
       12. The method of  claim 11 , wherein the biological sample is adipose tissue. 
     
     
       13. The method of  claim 4 , wherein the subject has a body mass index ( BMI )  less than about  27  kg/m   2    and has adipose tissue that is present in an amount that is greater than about  25   %  of the body weight of the subject.   
     
     
       14. The method of  claim 4 , wherein the subject has a BMI less than about  27  kg/m 2    and has adipose tissue that is present in an amount that is greater than about  30   %  of the body weight of the subject.

Join the waitlist — get patent alerts

Track USRE42129E — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.